Related Experiment Video
Updated: Feb 18, 2026
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Achieving quality 24-h blood pressure control with candesartan cilexetil
1Department of Medicine and Therapeutics, University of Glasgow, UK.
Insights
Candesartan cilexetil offers superior 24-hour blood pressure control compared to losartan. Its sustained efficacy and favorable trough-to-peak ratio enhance patient compliance and cardiovascular protection.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hypertension Management
Background:
- Optimal blood pressure control requires consistent 24-hour reduction.
- Antihypertensive agents need to be well-tolerated and effective with once-daily dosing for compliance.
- The renin-angiotensin system plays a key role in blood pressure regulation.
Purpose of the Study:
- To evaluate the sustained antihypertensive efficacy of candesartan cilexetil.
- To compare the 24-hour blood pressure lowering effects of candesartan cilexetil and losartan.
- To assess the trough-to-peak ratio as a measure of antihypertensive persistence.
Main Methods:
- Ambulatory blood pressure monitoring (ABPM) over 36 hours.
- Clinic blood pressure measurements up to 48 hours post-dosing.
- Calculation of trough-to-peak ratios for candesartan cilexetil and losartan.
Main Results:
- Candesartan cilexetil (8 and 16 mg) demonstrated trough-to-peak ratios close to the ideal 1.0.
- Losartan (50 mg) showed a trough-to-peak ratio of 0.7.
- Candesartan cilexetil (16 mg) exhibited significantly greater antihypertensive effects than losartan (100 mg) in ABPM and clinic measurements.
Conclusions:
- Candesartan cilexetil provides smooth, sustained 24-hour blood pressure control.
- Its slow dissociation from the AT1-receptor ensures long-lasting renin-angiotensin system suppression.
- Candesartan cilexetil offers improved efficacy and potential for enhanced cardiovascular protection, even with missed doses.
Abstract:
Epidemiological evidence suggests that optimal blood pressure control requires strategies that lower blood pressure consistently and fully throughout 24 h. In order to maximize compliance, antihypertensive agents also need to be well tolerated and effective when administered at a convenient once-daily dose. The new angiotensin II type 1 (AT1) receptor blocker candesartan binds tightly to, and dissociates slowly from, the AT1-receptor and thereby provides long-lasting suppression of the renin-angiotensin system. This is likely to explain its pronounced antihypertensive efficacy, which is maintained smoothly over 24 h. The trough-to-peak ratio is a useful measure of the persistence of antihypertensive efficacy at the end of the dosing interval. This ratio was found to be close to the ideal of 1.0 for candesartan cilexetil, 8 and 16 mg, whereas it was 0.7 for the prototype AT1-receptor blocker losartan, 50 mg. The antihypertensive effect of candesartan cilexetil, 16 mg, was also significantly greater than that of losartan, 100 mg, as demonstrated by ambulatory blood pressure measurements 0-36 h after dosing and by clinic measurements 48 h after dosing. By controlling blood pressure well beyond the normal dosing interval, candesartan cilexetil provides cardiovascular protection even in those patients who may occasionally miss doses.
Related Concept Videos
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:23Hypertension V: Nursing Management
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Errors occurring during blood pressure monitoring
Several factors...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:25Antihypertensive Drugs: Direct Renin Inhibitors